

## Operational highlights

- Strong performance by the South African business
- Successful unwinding of Netpartner cross shareholding
- Medicross acquisition of Prime Cure
- R1 billion value created for Health Partners for Life BEE shareholders
- Acquisition of a controlling 52,6% interest in GHG in the UK

**SA patient days**  
(days)



**SA length of stay**  
(days)




**SA EBITDA<sup>1</sup> margin**  
(%)



<sup>1</sup> Before BEE share-based expense

- 54% increase in Group revenue to R11,6 billion
- 11% growth in South African revenue to R8,2 billion
- 30% growth in Group operating profit to R1,6 billion
- 20,5% SA EBITDA<sup>1</sup> margin, up from 19,6%
- 20% growth in South African stand-alone adjusted<sup>2</sup> HEPS to 70,5 cents per share



<sup>1</sup> Before BEE share-based expense

<sup>2</sup> Adjusted to exclude BEE share-based expense and GHG effects